In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
The InChi Key for SLU-PP-332 is provided for unambiguous chemical identification
No Approved Medical or Performance Use Unlike peptides such as CJC-1295 or BPC-157, which have become popular in performance and recovery settings despite limited regulation, MOTS-c is not recognized in sports medicine and carries no approved clinical protocols for dosing, cycling, or long-term use
K.MatovA.et al (2017)
We have shown that obesity medications are safe and effective in patients with obesity who also have type 1 diabetes. Researchers obtained data from 250 adults aged 18 years and older with type 1 diabetes (mean age, 34 years
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820189.png)